CUDC-101 , ≥98% , 1012054-59-9

Synonym(s):
7-[[4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yl]oxy]-N-hydroxyheptanamide;Heptanamide, 7-[[4-[(3-ethynylphenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-N-hydroxy

CAS NO.：1012054-59-9

Empirical Formula: C24H26N4O4

Molecular Weight: 434.49

MDL number: MFCD15528940

PRODUCT Properties

• Melting point: 174-177℃
• Density: 1.28
• storage temp.: -20°C
• solubility: DMSO: soluble
• pka: 9.47±0.20(Predicted)
• form: solid
• color: White or off-white
• Stability: Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 1 month.
• InChIKey: PLIVFNIUGLLCEK-UHFFFAOYSA-N

Description and Uses

CUDC-101 (1012054-59-9) is a novel hybrid dual-acting HDAC and receptor tyrosine kinase inhibitor. It is a potent HDAC inhibitor which also inhibits EGFR and HER2,? IC50?= 4.4, 2.4 and 15.7 nM respectively.1?It not only blocks EGFR and HER2 but also attenuates multiple compensatory pathways such as AKT, HER3 and MET which enable tumor cells to escape the effects of conventional EGFR/HER2 inhibitors.1,2

CUDC-101 is a potent multi-acting HDAC (histone deacetylase), EGFR (epidermal growth factor receptor), and HER2 ( human epidermal growth factor receptor 2) inhibitor for the treatment of cancer.

Safety

• Symbol(GHS): GHS07
• Signal word: Warning
• Hazard statements: H315-H319-H335
• Precautionary statements: P280-P305+P351+P338
• WGK Germany: 3